Market reaction: what happened to Kenvue shares

Following the initial reports, Kenvue’s stock experienced a notable decline as investors weighed reputational and legal risks tied to one of the company’s best-known products. Short-term market swings reflect uncertainty; analysts caution that headlines can move share prices even before formal evidence or regulatory action emerges.

Sources reporting the market reaction include major outlets such as Financial Times, Investopedia, and Reuters coverage of the developing story.

What the RFK Jr.-led report may say

Reports indicate the HHS document could raise concerns about prenatal factors that may be associated with autism diagnoses, including prenatal acetaminophen exposure and maternal folate levels. At this stage, the suggestion is framed as a possible association rather than definitive causation.

It’s important to note that government agencies and many researchers treat epidemiological associations cautiously: correlation does not equal causation, and confounding factors can influence study outcomes.

Scientific context: where the evidence stands

Studies on prenatal acetaminophen exposure and neurodevelopmental outcomes have produced mixed results. Some observational studies have reported associations with autism or ADHD; others, including large population-based studies, have found no clear causal link. Medical experts emphasize that more rigorous research — including carefully controlled studies — is required to determine whether a causal relationship exists.

If you are pregnant or planning pregnancy, speak with your healthcare provider before making decisions about medication use. Leading health authorities continue to recommend using medications like acetaminophen as directed and only when necessary.

Kenvue’s response and next steps

Kenvue has reiterated that acetaminophen is approved for use during pregnancy when taken according to guidance and that no causal link to autism has been established. The company and regulatory authorities will likely monitor the report closely; any concrete regulatory changes would depend on strong scientific evidence and formal review.

The public and markets will also watch for legal implications. Prior litigation related to acetaminophen and developmental outcomes has typically faced high evidentiary hurdles.

What to watch

• The formal HHS report release (reported to be expected in the coming weeks).
• Reactions from independent public-health experts and peer-reviewed scientists.
• Any statements from Kenvue or regulatory bodies such as the FDA.
• Market responses and whether any legal actions follow.